Company: LHI
Filing Date: 2025-11-20
Form Type: F-1/A
Source: 0001213900-25-112807
Chunk: 25

Company: Living Homeopathy International Ltd.
Filing Date: 2025-11-20
Form: F-1/A
Chunk 25
---
see “ Dividend Policy” on page 51 of this prospectus), to all shareholders respectively in proportion to the shares they hold, regardless of whether the shareholders are U.S. investors or investors in other countries or regions. If Living Homeopathy incurs debt on its own in the future, the instruments governing such debt may restrict Living Homeopathy’s ability to pay dividends, make distribution or transfer funds to Living Homeopathy. Subject to the Company’s Act and our Amended and Restated Memorandum and Articles of Association, Living Homeopathy’s board of directors may authorize and declare a dividend to shareholders at such time and of such an amount as they think fit if they are satisfied, on reasonable grounds, that immediately following the dividend the value of Living Homeopathy’s assets will exceed its liabilities and Living Homeopathy will be able to pay its debts as they become due.

Other than LTO Holdings Ltd., our other shareholders
waived their right to dividends for each of the years ended March 31, 2024 and 2025 to leave profits within the Company. The Company
recorded constructive dividends of $983,560 and declared cash dividend $325,078 during the years ended March 31, 2025 and 2024, respectively.
to LTO Holdings Ltd., our controlling shareholder. See “Dividend Policy” beginning on page 51 of this prospectus for
further details. Since the end of the year ended March 31, 2025, the Company has not declared any dividends. As of the date of this prospectus,
Living Homeopathy does not have any U.S. investors, so no dividends or distributions have been made to any U.S. investors. Both Living
Homeopathy and Living Homeopathy Hong Kong currently intend to retain all available funds and future earnings, if any, for the operation
and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future. Any future determination
related to our dividend policy will be made at the discretion of Living Homeopathy’s board of directors after considering our financial
condition, results of operations, capital requirements, contractual requirements, business prospects and other factors the board of directors
deems relevant, and subject to the restrictions contained in any future financing instruments.

Within our direct holding structure, the cross-border transfer of funds within our corporate structure is legal and compliant with the laws and regulations of the Cayman Islands and Hong Kong. In the future, cash proceeds from overseas financing activities, including this offering, can be directly transferred to subordinate